RECOMBINANT POLYPEPTIDES FOR PROGRAMMING EXTRACELLULAR VESICLES

Herein is provided a recombinant tumor-selective viral particle comprising a nucleic acid encoding a recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, said recombinant polypeptide comprising: at least one targeting moiety for directing said EV to said a...

Full description

Saved in:
Bibliographic Details
Main Authors BELL, John Cameron, PAUMIER, Yoanna Poutou, DUONG, Jessie Nhan, SINGARAVELU, Ragunath, MOHAMMADIAZAD, Mohammadtaha, ATHERTON, Matthew John, LICHTY, Brian Dennis, WANG, Fuan, ILKOW, Carlolina Solange, WHELAN, Jack Timothy, BOULTON, Stephen Donald, CRUPI, Mathieu François Joseph
Format Patent
LanguageEnglish
Published 29.06.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Herein is provided a recombinant tumor-selective viral particle comprising a nucleic acid encoding a recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, said recombinant polypeptide comprising: at least one targeting moiety for directing said EV to said at least one target molecule expressed by said at least one target cell; at least one EV-anchoring polypeptide; and at least one intravesicular polypeptide. The viral particle may be from an oncolytic viruses. Recombinant polypeptides for programming EVs to target particular molecules are also provided. Also described are therapeutic EVs for delivering payload polypeptides (and/or cargo molecules) to target cells, e.g., in vaccine or cell-free "CAR-T"-like applications, along with EVs for recruiting immune cells to target cells in EV-mediated BiTE -like applications. Oncolytic viruses may also be engineered to infect tumor cells and shed programmed EVs, yielding additional therapeutic effects.
Bibliography:Application Number: US202017780129